DSG Capital Advisors’s AstraZeneca AZN Stock Holding History

DSG Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,172	Closed	-$231K	–	119
2026 Q1	$231K	Sell	1,172 -28	-2%	-$5.4K	0.04%	120
2025 Q4	$226K	Buy	+1,200	New	+$210K	0.03%	114

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

DSG Capital Advisors's AZN Position: Q2 2026 in Review

DSG Capital Advisors sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 1,172 shares — an estimated $231K sold.

DSG Capital Advisors first reported a position in AZN in Q4 2025 and held it in 2 quarters. The position peaked at $231K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

DSG Capital Advisors reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
DSG Capital Advisors sold 1,172 AstraZeneca shares in Q2 2026, an estimated $231K.
DSG Capital Advisors first reported a position in AstraZeneca in Q4 2025 and held it in 2 quarters.
DSG Capital Advisors's AstraZeneca position peaked at $231K in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on DSG Capital Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.